NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone for preventing ischemic strokes in patients with acute noncardioembolic ...

Please provide your email address to receive an email when new articles are posted on . Societies issued new guidelines for the screening and treatment of stroke. The new document provides ...

As stroke risk rises for women as they age — especially after menopause — a new long-term study suggests that what they eat may play a powerful role in lowering that risk. Stroke is a leading cause of ...

Candice Maenza received salary support from a National Institutes of Health grant. Robert Sainburg receives funding from the National Institutes of Health, National Institute of Child Health and ...

Deaths from both causes are down, but they still eclipse all other causes, according to new statistics. By Nina Agrawal Despite gains in treatment, cardiovascular disease remains the leading cause of ...

When Donald Trump won his second term in the White House, he was the oldest man in the history of the United States to do so. Assuming he serves for his entire term, he’ll be 82 years and seven months ...

In the absence of much federal action, states have enacted dozens of laws this year to lower prescription drug costs for their residents—and many more are considering following suit. The first ...

In the absence of much federal action, states have enacted dozens of laws this year to lower prescription drug costs for their residents—and many more are considering following suit. The first ...

A warehouse worker consumed 8 energy drinks a day to "stay alert" at work, which led to a dangerous health condition Cara Lynn Shultz is a writer-reporter at PEOPLE. Her work has previously appeared ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...

Asundexian reduced ischemic stroke risk without increasing major bleeding in the OCEANIC-STROKE study, meeting primary efficacy and safety endpoints. The study included 12,327 patients with acute ...

Asundexian (Bayer) significantly reduces the risk of ischemic stroke compared with placebo, without increasing the risk of major bleeding, when used for secondary stroke prevention in patients treated ...